COST-EFFECTIVENESS ANALYSIS OF LURASIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Priyadarshini, M. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1380
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH40
引用
收藏
页码：A188 / A189
页数：2
相关论文
共 50 条
  • [21] Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
    Tunis, SL
    Johnstone, BM
    Gibson, PJ
    Loosbrock, DL
    Dulisse, BK
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 38 - 45
  • [22] COST-EFFECTIVENESS ANALYSIS OF DIFFERENT TREATMENT STRATEGIES FOR SCHIZOPHRENIA IN CHINA
    Du, X. M.
    Huang, Y.
    VALUE IN HEALTH, 2023, 26 (06) : S126 - S126
  • [23] A cost-effectiveness analysis model for treatment of chronic schizophrenia in Mexico
    Mould, J
    Contreras-Hernandez, I
    Verduzco, W
    Garduño-Espinosa, J
    VALUE IN HEALTH, 2006, 9 (03) : A67 - A67
  • [24] A cost-effectiveness clinical decision analysis model for treatment of schizophrenia
    Palmer, CS
    Brunner, E
    Ruíz-Flores, LG
    Paez-Agraz, F
    Revicki, DA
    ARCHIVES OF MEDICAL RESEARCH, 2002, 33 (06) : 572 - 580
  • [25] Investigation of Safety Profile of Lurasidone and Olanzapine in Treatment of Schizophrenia
    Divea Sharma
    Amit Nayak
    D. D. Dupta
    Shashank Sharma
    Dinesh Dutt Sharma
    SN Comprehensive Clinical Medicine, 6 (1)
  • [26] COST-EFFECTIVENESS ANALYSIS OF PHARMACOGENETIC TESTING TO GUIDE TREATMENT IN SCHIZOPHRENIA
    Khani, Noushin Saadullah
    Murtough, Stephen
    Richards-Belle, Alvin
    Varney, Lauren
    Cotic, Marius
    Abidoph, Rosemary
    Barrett, Barbara
    Jin, Huajie
    Bramon, Elvira
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2024, 87 : 253 - 253
  • [27] COST EFFECTIVENESS OF LURASIDONE, QUETIAPINE, AND OLANZAPINE MONOTHERAPY IN THE TREATMENT OF BIPOLAR I DISORDER DEPRESSION
    Bhagvandas, N. S.
    Hay, J. W.
    VALUE IN HEALTH, 2016, 19 (03) : A188 - A188
  • [28] A POPULATION-BASED COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE AND RISPERIDONE AMONG AMBULATORY PATIENTS WITH SCHIZOPHRENIA
    Cooper, Dan
    Moisan, Jocelyne
    Abdous, Belkacem
    Gregoire, Jean-Pierre
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2008, 15 (03): : E385 - E397
  • [29] Antipsychotic treatments for schizophrenia: A cost-effectiveness analysis comparing haloperidol, olanzapine, risperidone and ziprasidone.
    Augustovski, F
    Krupitzky, H
    Laffaire, E
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 162 - 162
  • [30] Cost and effectiveness of switching from risperidone to olanzapine in the treatment of schizophrenia
    Faries, D
    Ascher-Svanum, H
    Nyhuis, AW
    Kinon, BJ
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 118S - 118S
12345